Show simple item record

dc.contributor.authorMarcovecchio, Loredana
dc.contributor.authorDunger, David
dc.contributor.authorBruggraber, Sylvaine
dc.contributor.authorMander, Adrian
dc.contributor.authorTree, Timothy
dc.contributor.authorSchulte, Anke
dc.contributor.authorMathieu, Chantal
dc.contributor.authorKinp, Mikael
dc.contributor.authorChmura, Piotr
dc.date.accessioned2022-04-11T23:30:42Z
dc.date.available2022-04-11T23:30:42Z
dc.date.issued2022-05-18
dc.identifier.issn1745-6215
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/335998
dc.description.abstractBackground: The INNODIA consortium has established a pan-European infrastructure using validated centres to evaluate prospectively clinical data from individuals with newly diagnosed Type 1 diabetes combined with centralized collection of clinical samples to determine rates of decline in beta-cell function and identify novel biomarkers, which could be used for future stratification of Phase 2 clinical trials. Methods: In this context we have developed a Master Protocol, based on the “backbone” of the INNODIA natural history study, which we believe could improve the delivery of Phase 2 studies exploring the use of single or combinations of Investigational Medicinal Products (IMPs), designed to prevent or reverse declines in beta-cell function in individuals with newly diagnosed Type 1 diabetes. Although many IMPs have demonstrated potential efficacy in Phase 2 studies, few subsequent Phase 3 studies have confirmed these benefits. Currently Phase 2 drug development for this indication is limited by poor evaluation of drug dosage and lack of mechanistic data to understand variable responses to the IMPs. Identification of biomarkers which might permit more robust stratification of participants at baseline has been slow. Discussion: The Master Protocol provides: 1) standardized assessment of efficacy and safety; 2) comparable collection of mechanistic data; 3) the opportunity to include adaptive designs and the use of shared control groups in the evaluation of combination therapies; 4) benefits of greater understanding of endpoint variation to ensure more robust sample size calculations and future baseline stratification using existing and novel biomarkers.
dc.publisherBioMed Central
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleINNODIA Master Protocol for the evaluation of investigational medicinal products in children, adolescents and adults with newly diagnosed type 1 diabetes
dc.typeArticle
dc.publisher.departmentDepartment of Paediatrics
dc.date.updated2022-04-09T14:56:29Z
prism.publicationNameTrials
dc.identifier.doi10.17863/CAM.83430
dcterms.dateAccepted2022-03-30
rioxxterms.versionofrecord10.1186/s13063-022-06259-z
rioxxterms.versionVoR
dc.contributor.orcidMarcovecchio, Loredana [0000-0002-4415-316X]
rioxxterms.typeJournal Article/Review
cam.issuedOnline2022-05-18
cam.orpheus.success2022/06/01
cam.orpheus.counter3
cam.depositDate2022-04-09
pubs.licence-identifierapollo-deposit-licence-2-1
pubs.licence-display-nameApollo Repository Deposit Licence Agreement


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International